Matthew Finston
Latest Articles
HTG Molecular: The Future Of Diagnostic Profiling
Cheniere Energy - Carl Icahn's Big Energy Buy
Hedge Fund Tea Leaves: Fisher Asset Management
'Regarding Creative Edge Nutrition' What I Sent To The SEC
MusclePharm: It's All About The Cash
Brazil's Fire Sale
CEN Biotech: The Rejection Is Final, But The Sad Saga Continues
Chinese ETFs: Year Of The Bear? Naw, It's The Year Of The Sheep
Building The Pot Stock Portfolio For The 'Risk-Adverse' Investor (Pun Intended)
Financial Insecurity: Occupy A Short On China
Pot Stock Crash Redux: $23.3B Loss?
Marijuana Stocks: Seeking Liquidity
Seeking Baupost: The Hidden Holdings - Part III
Elekta AB: Slippery Bottom-Line Makes This Tough To Squeeze
Short Heard 'Round The World: Giving The World A Squeeze - Part 2
Seeking Baupost: 'Feel-Good' Bubble Disturbs Hedge Fund Yeti - Part II
Seeking Blackrock: Swimming With The Alpha Whale
Transocean Downgrade Incites Investors Into Mini Panic
Seeking Daruma: Zen And The Art Of Small Cap Investing
Keeping Up With The Contrarians
Soros Dumps Apple, Buys China
Seeking Baupost: The Pangs Of Value Investing - Part 1
China: The Short Heard 'Round The World - Part 1
Health Canada Rejects Cen Biotech's Application
BlackRock Hints 'Big Oil' Has Bottomed
A Scandal On Edge
InvenSense: Why I Jumped In After Earnings (Again)
Taking The Creative Way Out
Pot Stock Millionaires: Hemp Inc. - Part III
Pot Stock Millionaires: MyECheck - Part II
Did Health Canada Inflate The Potential Of The Marijuana Market?
Canada's Marijuana Market: The Good, Bad, And Ugly